AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04642365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered as per the schedules specified in the respective arms.
Study NCT04642365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Study NCT04995549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutiscan® CS 100
Description: Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
Study NCT06156241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Stem cells derived from human cord tissue.
Study NCT05313737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated message
Description: Automated message via phone call (audiocare)
Study NCT05313737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-out scheduling
Description: Scheduling via non-automated phone call
Study NCT05699564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early biomarker-based cardiological assessment
Description: We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
Study NCT05417087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
Study NCT05417087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Hydrobromide Tablets
Description: Vortioxetine Hydrobromide Tablets 20mg
Study NCT05244733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Engage (S-ENGAGE)
Description: S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
Study NCT05244733 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Healthy Lifestyles Education Program
Description: The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
Study NCT05526339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation combined with nasopharyngeal airway
Description: The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
Study NCT05126537 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: prospective and observational study with no intervention
Study NCT05526339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal cannula combined with nasopharyngeal airway
Description: The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
Study NCT05852236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Pressure ulcer care package application.
Study NCT05969340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ultra-high-resolution CT-scan
Description: Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
Study NCT05969340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultra-high-resolution CT-scan
Description: Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
Study NCT05750550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 1
Description: anti-TRBV9 monoclonal antibody single infusion at dose 1
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 2
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 2
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 3
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 3
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 4
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 4
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 5
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 5
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 6
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 6
Study NCT05407779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-180, dose 7
Description: anti-TRBV9 monoclonal antibody, single infusion at dose 7
Study NCT06330337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide（TMZ） injection or oral administration
Description: Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.
Study NCT06330337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Albumin-Bound Paclitaxel(ABX) intravenous drip
Description: ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle
Study NCT06330337 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Specific mode electroacupuncture stimulation(SMES) intervention
Description: Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8.
Study NCT05096416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The three-dimensional (3D) printed hemodialysis vascular model
Description: The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
Study NCT05439408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD 100 mg
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
Study NCT05439408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 140 MG [Sprycel]
Description: SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
Study NCT05945251 — intervention group
Intervention type: OTHER
Intervention: Internet-delivered cognitive behavioral therapy
Description: Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
Study NCT05665907 — intervention group
Intervention type: OTHER
Intervention: Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
Description: Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
Study NCT05279820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial pulpotomy
Description: Partial pulp tissue amputation
Study NCT05279820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Pulpotomy
Description: Full Pulpotomy
Study NCT05367843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIME-2-CoV_Beta
Description: Intramuscular (IM) injection
Study NCT06069635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol (repeated sprint ability)
Description: The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
Study NCT06069635 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control group
Description: approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
Study NCT05781464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator).
Study NCT05781464 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator).
Study NCT05781464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged slow expiration technique
Description: The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
Study NCT06043973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almonertinib
Description: The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
Study NCT05691647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronotherapy
Description: Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, they will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.
Study NCT05691647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
Study NCT05691647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
Study NCT05405101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation of aldosterone producing adenoma.
Description: On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance.
Study NCT05405101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral adrenalectomy
Description: Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in >1-2 patients)
Study NCT06423131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCRαβ Depleted haploidentical HCT
Description: Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
Study NCT04792632 — intervention group
Intervention type: DEVICE
Intervention: Veye Lung nodules
Description: Veye Lung Nodules
Study NCT06315699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate Tablets
Description: The dose was administered 2mg once daily in a double-blind random crossover method
Study NCT06315699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fructose
Description: The dose was administered 2mg once daily in a double-blind random crossover method
Study NCT05263973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
Study NCT05863065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to a Virtual Reality scenarios
Description: Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
Study NCT05749159 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: physiotherapy
Description: New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
Study NCT05749159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
Study NCT06435052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization & Reprocessing Therapy
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
Study NCT06435052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
Study NCT05633706 — intervention group
Intervention type: DEVICE
Intervention: fluid biopsy capsule
Description: Collection of a fluid biopsy from the small intestine via ingestible capsule
Study NCT05687110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04730531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration with 0.25% bupivacaine and epinephrine
Description: The local infiltration will occur in 2 stages, separated by 30 minutes. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
Study NCT04730531 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of equal volume injectable saline
Description: An equal volume of injectable saline will be used in the exact 2 stages as the treatment group. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
Study NCT06434467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine injection
Description: Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
Study NCT05795153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 (Open-Label) taken orally for 12 weeks
Study NCT05122299 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Negative control group
Description: No intervention after extraction then delayed implant insertion at the site of extraction after three months
Study NCT05122299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postive control
Description: Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.